Novel advances in rapid manufacturing, deployment, and delivery of intranasally administered drugs and biologics

ONdrugDelivery

Volumn , Issue APRIL, 2011, Pages 31-34

  Sullivan, Timothy ^a  

^a Mystic Pharmaceuticals Inc 2006   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDIABETIC AGENT; ANTIEMETIC AGENT; BACTERIAL VACCINE; DNA VACCINE; INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE; VACCINE;

2009 H1N1 INFLUENZA; ANALGESIA; ANAPHYLACTIC SHOCK; ANTHRAX; ARTICLE; BLISTER PACK; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG MANUFACTURE; DRUG PACKAGING; DRUG SAFETY; DRUG STABILITY; DRUG STORAGE; EBOLA VIRUS; FREEZE DRYING; HEALTH CARE PERSONNEL; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOCOMPETENT CELL; INFLUENZA A (H5N1); INTRANASAL DRUG ADMINISTRATION; NOSE CONGESTION; NOSE MUCOSA; PARTICLE SIZE; PATIENT COMPLIANCE; PLAGUE; SMALLPOX; THERMOSTABILITY; TRAFFIC AND TRANSPORT; UNITED STATES;

EID: 84856281343     PISSN: None     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (12)

1. Secretary Kathleen Sebelius, US Department of Health and Human Services, "Review for New Federal Approach to Medical Countermeasures Press Release." August 19, 2010.
2. Hickey, Anthony J. "Formulation of a Dry Power Influenza Vaccine for Nasal Delivery." AAPS PharmSciTech 2006, Article 19.
3. Shahiwala, Aliasgar. "Nanocarriers for Systemic and Mucosal Vaccine Delivery." Bentham Science Publishers Ltd, December 4, 2006.
4. Alcock, Robert. "Long Term Thermostablization of Live Poxviral and Adenoviral Vaccine Vectors at Supraphysiological Temperatures in Carbohydrate Glass" Sci Transl Med, Vol 2, Issue 19, February 17, 2010.
5. Global Industry Analyst, Inc., Intranasal Drug Delivery, June 2007.
6. Asanuma H, Hirokawa K, Uchlyama M, Suzuki Y, Aizawa C, Kurata T, Sata T, Tamura S. "Immune responses and protection in different strains of aged mice immunized intranasally with an adjuvantcombined influenza vaccine." Vaccine, July 2001;19(28-29): 3981-3989.
7. Pires A, Fortuna A, Gilberto A, Falcao A. "Intranasal Drug Delivery: How, Why and What for?" J Pham Pharmaceut Sci Oct 2009:12(3) 288-311.
8. Illum L. "Nasal Drug Delivery: New Developments and Strategies." Drug Discov Today, 2002;7:1184-1189, PubMed DOI: 10.1016/S1359-6446(02)02529-1.
9. Groneberg DA, Witt C, Wagner U, Chung KF, Fischer A. "Fundamentals of Pulmonary Drug Delivery." Respir Med. 2003;97:382-387, PubMed DOI: 10.1053/rmed.2002.1457.
10. Roth Y, Chapnik JS, Cole P. "Feasibility of Aerosol Vaccination in Humans." Ann Otol Rhinol Laryngol. 2003 Mar;112(3):264-270, U.S National Library of Medicine, PubMed.gov
11. Mutsch M, Zhou W, Rhondes P, Bopp M, Chen R, Linder T, Spyr C, Steffen R. "Use of the Inactivated Intranasal Influenza Vaccine and the Risk of Bell's Palsy in Switzerland." NEJM 2004;350:986-903.
12. Zhou W, Pool V, DeStefano F, Iskander JK, Haber P, Chen RT. "A Potential Signal of Bell's Palsy After Parenteral Inactivated Influenza Vaccines." VAERS Working Group. Epidemiology Program Office, Centers for Disease Control and Prevention, commented in Pharmacoepidemiol Drug Saf. 2004 Aug;13(8):505-10.